Context: Impairments of muscle function and strength in patients with primary hyperparathyroidism (PHPT) are rarely addressed, although decreased muscle function may contribute to increased fracture risk. Objective: We aimed to assess the changes in muscle strength, muscle function, postural stability, quality of life (QoL), and well-being during treatment with vitamin D or placebo before and after parathyroidectomy (PTX) in PHPT patients. Design: A randomized placebo-controlled trial. Patients: We included 46 PHPT patients, mean age 58 (range 29-77) years and 35 (76%) were women. Interventions: Daily treatment with 70 mg (2800 IU) cholecalciferol or placebo for 52 weeks. Treatment was administered 26 weeks before PTX and continued for 26 weeks after PTX. Main outcome measures: Changes in QoL and measures of muscle strength and function. Results: Preoperatively, 25-hydroxyvitamin D (25OHD) increased significantly (50-94 nmol/l) compared with placebo (57-52 nmol/l). We did not measure any beneficial effects of supplementation with vitamin D compared with placebo regarding well-being, QoL, postural stability, muscle strength, or function. In all patients, we measured marked improvements in QoL, well-being (P!0.01), muscle strength in the knee flexion and extension (P!0.001), and muscle function tests (P!0.01) after surgical cure. Postural stability improved during standing with eyes closed (P!0.05), but decreased with eyes open (P!0.05). Conclusions: Patients with PHPT and 25OHD levels around 50 nmol/l did not benefit from vitamin D supplementation concerning muscle strength, muscle function, postural stability, well-being, or QoL. Independent of preoperative 25OHD levels, PTX improved these parameters.
Introduction
The risk of fracture is increased in patients with primary hyperparathyroidism (PHPT) (1) and bone mineral density (BMD) is reduced compared with healthy controls (2) . Muscle strength and quality of life (QoL) is also impaired in PHPT (3) , which may contribute to increased fracture risk independently of BMD. Muscle function is a central topic of debate and focus in clinical research (4) . Muscle strength and function are obviously necessary for basic locomotion and increasingly important for persistent mobility and independency with aging. Furthermore, muscles interact with bones in both direct and indirect ways (5) , which highlights the importance of physical activity in the elderly and in patients at increased risk of fracture.
Several mechanisms of action may account for the impaired QoL and muscle function in PHPT, including the increased plasma levels of PTH (6, 7, 8) . PTH receptors are expressed by muscle tissue (7) and in the CNS (7) . Moreover, increased plasma calcium (Ca 2C ) in PHPT may also be part of the explanation, due to the wellcharacterized involvement of Ca 2C in muscle contractions (9) . Finally, low plasma levels of vitamin D (25OHD) are known to affect muscle strength and function and low levels are more common in PHPT than in healthy controls (10, 11) . The vitamin D receptor is expressed by muscle tissue (12) and treatment with vitamin D has been shown to improve muscle strength (13) and increase muscle fiber size (12) in patients with low 25OHD levels. However, previous studies were often lacking a control group, a randomization procedure, a blinding procedure, or a combination of these limitations. The classical treatment of PHPT is by parathyroidectomy (PTX) with removal of pathologic parathyroid tissue. Several studies have suggested that this operation improves both QoL and muscle strength (8, 14, 15, 16) . However, with the current change in clinical presentation to mild or asymptomatic PHPT, surgery may not always be necessary (17) . A treatment option in these patients includes vitamin D supplementation (18) . In this randomized controlled trial (RCT) (19) , PHPT patients with low 25OHD levels were randomized to 26 weeks of treatment with vitamin D or placebo before PTX followed by 26 weeks of continuous treatment after surgery. We have previously shown that preoperative vitamin D supplementation safely increased 25OHD by 88%, reduced PTH levels by 17%, and improved BMD at the lumbar spine by 2.5% without observing changes in plasma or urinary calcium (19) . The primary endpoint was a decrease in PTH preoperatively. We now also report data on the secondary endpoints muscle strength, muscle function, postural stability, and QoL.
Subjects and methods

Participants and study design
We only included PHPT patients with vitamin D insufficiency (25OHD !80 nmol/l) and established mildto-moderate hypercalcemia (plasma Ca 2C !1.60 mmol/l) (19) . The study was an investigator-initiated double-blind, randomized, placebo-controlled, parallel-group trial comparing treatment with a daily oral supplement of 70 mg (2800 IU) cholecalciferol (vitamin D3) or similar placebo for 1 year. The treatment was administered for 6 months before PTX (at week 26G4 weeks) and continued for 6 months following PTX. The study was performed in accordance with the Declaration of Helsinki II and guidelines on Good Clinical Practice (GCP). The GCP Unit at Aarhus University Hospital monitored the study. The study was approved by the Danish Data Protection Agency, the Ethical Committee of Central Denmark Region (#M20080011), and registered at ClinicalTrials. gov (#NCT00674154).
Muscle strength and function
We assessed the maximal voluntary isometric muscle strength both at the upper-and lower extremities with an adjustable dynamometer chair as previously reported (3). The method is known to be highly reliable (reliability coefficients (rc) of 0.88-0.96) for both upper end lower extremities (20) . Maximal strength was measured in Newton (N) and maximal force production in N/s. We used two physical function tests to assess performance comparable to daily activities. The first test was the time for ten repeated chair stands (RCS) without the use of hands. Secondly, the Timed Up and Go test (TUG), i.e. time to stand up from a chair, walk 3 m, and return to the chair. The RCS test has a high level of reliability (rcZ0.84), whereas the TUG test has a moderate reliability (rcZ0.57) (20) . Both tests discriminate well between functional levels (20) and are easy to use in the daily clinic. The muscle strength and functional tests were performed at week 0 (baseline), 25 (preoperative), and 52 (postoperative).
Postural stability
We assessed postural stability with the use of a stadiometer as previously detailed (3). The stadiometer records length (mm) and speed (mm/s) of the sway in medio-lateral and anterior-posterior direction. The data are presented as velocity moment (VM, mm 2 /s), which is a product of total length of sway in both directions per second. The stadiometer has an acceptable reliability coefficient (rcZ0.53) (20) . We measured postural stability under four different settings: i) normal standing with eyes open; ii) normal standing with eyes closed; iii) semitandem, and iv) tandem standing. We adjusted the best result (lowest VM) for differences in body height to scaled velocity moment (SVM)Z(VM/(height in cm) 2 )!180 2 .
Biochemistry
We used standard laboratory methods for the measurements of creatinine kinase (CK) and lactate dehydrogenase (LDH). We collected blood samples before testing muscle strength and function. Analyses of vitamin D metabolites, vitamin D-binding protein, PTH, bone markers, creatinine, albumin, alkaline phosphatase, and plasma and urinary levels of calcium and phosphate were analyzed using goldstandard methods and presented previously (19) . (3, 14, 15, 21, 22) . The WHO-5 index of well-being consists of five questions and answers are scored from 0 to 5. The score is multiplied by 4 and presented as a total percentage from 0 to 100. A well-being score below 50% indicates depressive affection (sensitivity 89% and specificity 86%), and a score below 28% suggests depression (23) .
Quality of life
Body composition
Using dual-energy X-ray absorptiometry (DXA, Hologic Discovery, Hologic, Inc., Waltham, MA, USA), we assessed body composition by whole-body scan at week 0, 25, and 52. As these scans were added to the protocol after initiation of the study, we only report measures from week 25 and 52. Assessments include total and subtotal body mass, lean body mass, and fat mass (g). We calculated BMI as body weight divided by the square of the height (kg/m 2 ).
Statistical analyses
We analyzed all data with the intention-to-treat approach.
We assessed differences between groups using the Student's (19) . Hence, we planned to include 50 PHPT patients. We used STATA 10.0 for all statistical analyses.
Results
Subjects, PTH, and vitamin D
The characteristics of 46 included patients are given in Table 1 . Forty-two patients completed the preoperative 25 weeks of the study and 40 patients completed all 52 weeks of study. The treatment was well tolerated and with a high level of compliance (96%). During the preoperative phase, 25OHD increased significantly (50 (G20) nmol/l to 94 (G18) nmol/l) compared with placebo group (57 (G18) nmol/l to 52 (G18) nmol/l) and caused a PTH decrease by 17% (PZ0.01; absolute difference 2.4G1.2 pmol/l) in the vitamin D group. Plasma creatinine, and plasma or urinary calcium levels did not change significantly. Table 2 gives the results on muscle strength measurements. At baseline, muscle strength (N) and muscle force production (N/s) did not differ between groups at any of the measured muscle groups. Compared with placebo, vitamin D treatment did not cause significant changes in hand grip strength or muscle strength at elbow extension/ flexion or knee extension/flexion before PTX (baseline to week 25) or following surgery (week 26-52). Neither did max force production differ between groups in response to treatment (data not shown). Furthermore, the correlations between 25OHD levels and muscle strength measurements were not significant at baseline or after interventions. Table 2 also gives changes in muscle strength within the entire group of patients independent of treatment allocation. Muscle strength improved significantly at knee extension and flexion at 608 before surgery, and all measures at the knee improved following PTX. Improvements were only borderline significant after PTX at hand grip (PZ0.07) and elbow flexion (PZ0.08). Similar to the findings on muscle strength, muscle force production at most muscle groups increased after PTX in the entire group of patients (data not shown). No significant correlations were found between changes in plasma levels of 25OHD, PTH, or Ca 2C and changes in muscle strength.
Muscle strength
Muscle function
Treatment with vitamin D did not cause significant changes in the TUG or the RCS test compared with placebo. In the entire group of patients, the RCS test improved significantly before PTX (11%, P!0.001) as well as following surgery (8%, P!0.001), whereas the TUG test only improved following surgery (10%, P!0.01). The postoperative changes were not significantly correlated with changes in plasma levels of PTH, 25OHD, or Ca 2C .
Postural stability
Measurement of postural stability showed no effects of vitamin D treatment compared with placebo ( QoL and well-being Figure 1 shows the percentage change in norm-based scores of QoL between time points of measurements as assessed by the SF-36 questionnaire for the eight subdomains and two component scores. Preoperatively, QoL scores improved in the placebo compared with the vitamin D group in the RP and GH domain causing an improved PCS, whereas indices of mental health (VT, SF, RE, MH, and MCS) did not change significantly between groups before PTX. Postoperatively, changes in scores did not differ significantly between groups. For all patients, we found a significant postoperative improvement in six of eight domains. This caused an overall improvement in the MCS (PZ0.004), whereas the PCS only improved borderline significantly (PZ0.09).
The WHO-5 index of well-being and changes over time did not differ between groups. Postoperatively, there was an improvement in the entire group of patients from a median score of 64 (IQR: 44;80) to 76 (IQR: 54;82) (P!0.01).
CK and LDH
As shown in Fig. 2 , during the 52 weeks of study, vitamin D treatment did not affect plasma levels of CK (ANOVA PZ0.74) or LDH (ANOVA PZ0.74). The P value indicates between group differences.
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Assessment of effects of PTX in the entire group of patients (independent of treatment allocation) showed an increase in CK levels from a median of 78 (IQR: 50;109) to 86 (IQR: 69;125) U/l during the 52 weeks of follow-up (P!0.01). Before surgery, CK levels did not change, whereas CK levels increased by 14% (IQR: 0;47%) following surgery (P!0.01). Similarly, LDH levels increased by 12% (CI: 8;17%, P!0.001) from 171 (CI: 159;183) to 191 (CI: 178;203) U/l in the entire group of patients during the 52 weeks of follow-up. The levels did not change before PTX, but increased postoperatively by 11% (CI: 7;16%, P!0.001).
Discussion
Muscle function and strength are known to be impaired in PHPT (3) . As low vitamin D levels are often encountered in patients with PHPT and are known to exert adverse effects on muscle performance, we investigated whether low vitamin D levels may be an explanation for a reduced muscle function in PHPT. However, in our RCT, the baseline 25OHD levels were around 50 nmol/l and patients did not benefit from preoperative vitamin D supplementation with regard to muscle function. Neither did the treatment improve QoL, well-being, or postural stability. However, muscle strength, muscle function, well-being, and QoL improved significantly following PTX, suggesting that physical and neurophysiological impairments in patients with PHPT are not attributable to low vitamin D levels but rather to the disease itself.
Our findings of a preoperative increased QoL score in the RP and GH domains resulting in an improved MCS score in the placebo group compared with the vitamin D group were against our a priori expectation of beneficial effects of vitamin D. In groups of patients without PHPT, low plasma 25OHD have also been associated with reduced QoL (24) , and an RCT suggested improved QoL after vitamin D repletion (25) . It is well known that PHPT is associated with a reduced QoL as measured by SF-36 (27) , and may exert negative effects on neuronal function and synaptic plasticity (28) . Moreover, receptors for PTH are expressed in central nervous tissues (7) and high PTH levels may adversely affect psychological and cognitive functions (6), as well as elevated PTH and Ca 2C levels may cause cerebral hypoperfusion (29) . However, as treatment with vitamin D in our study caused a 17% decrease in PTH levels without affecting plasma Ca 2C levels (19) , such mechanisms of action do not seem to provide an appropriate explanation for our findings. Moreover, it may be questioned whether slightly elevated levels of Ca 2C and PTH actually affects QoL, as QoL does not seem to be impaired in mild hyperparathyroid hypercalcemia caused by familiar hypocalciuric hypercalcemia (30) . Further studies are needed to evaluate the effect of vitamin D supplementation on QoL in patients with PHPT including disease-specific questionnaires.
The increased risk of fracture in PHPT patients may be due to one or more of the following: low BMD, decreased muscle strength, decreased muscle function, and impaired postural stability (3). Hence, we applied a number of tests which have been shown to predict risk of falls and fractures. The RCS has been associated with risk of hip fractures (31) and the TUG test has been associated with the risk of falling (32) . Moreover, postural sway and strength at knee extension/flexion has been associated with risk of falling (32, 33) . Importantly, treatment of low vitamin D levels improves bodily sway, number of falls, and TUG in RCTs (34, 35) . Despite studying a population of PHPT patients with vitamin D insufficiency, our intervention with a daily high dose of vitamin D did not improve physical performance compared with placebo. Neither did our intervention affect lean tissue mass or biochemical markers of muscle tissue, suggesting that the physical impairment in PHPT is not due to low vitamin D levels when baseline 25OHD levels are around 50 nmol/l.
Despite no beneficial effect of the intervention with vitamin D on measured indices, our study does suggest positive effects of PTX on QoL and muscle function, which is in accordance with the findings from several previous observational studies (16, 27) . Accordingly, we found that PTX was associated with a better WHO-5 index of wellbeing and an improvement in six of eight subdomains of the SF-36 questionnaire. Moreover, muscle strength increased and results of RCS and TUG improved. Our findings of increased CK and LDH levels may be caused by increased physical activity following PTX. Biochemical levels of CK are considered as a quantitative marker of muscle tissue and may reflect skeletal muscle micro trauma (36) . CK is known to increase and peak 1-4 days after different types of exercise and may remain elevated for several days (37) . The resting values of CK are therefore also elevated in physically active individuals compared with non-active controls (38) . The small but significant increases in CK and LDH in this study may consequently be a result of increasing physical activity after PTX. Effects of PTH on muscle tissue have previously been studied by Reppe et al. (7), showing a marked dysregulation of muscle gene expression in patients with PHPT, which was especially pronounced for genes regulating proteins involved in the contractile process. Hence, the authors report PTH-induced upregulation in 46 of 50 relevant genes which may lead to a state of local energy insufficiency due to marked increased activity (7). Muscle-specific energy insufficiency might explain the muscle weakness in PHPT and the improvements seen after PTX. If so, the preoperative decrease in PTH levels in response to vitamin D supplementation as observed in our study may not be large enough to exert such beneficial effects. The major strength of our study is the randomized, placebo-controlled, double-blind design. We used well validated questionnaires, tests, assays, and other equipment to assess effects. However, the strength of the study is limited by the relatively small number of participants. With 40 patients completing the study, we cannot exclude that a statistical type II error may apply to our findings. Also, a statistical type I error could explain the preoperative improvement of QoL in the placebo group. Although we aimed to include patients with vitamin D insufficiency, we cannot exclude that the mean baseline 25OHD level of 54 nmol/l was too high, the sample size too small, or the treatment duration too short to detect beneficial effects of preoperative vitamin D supplementation. In studies with very low baseline 25OHD values, muscle strength and muscle fiber size have been shown to increase after vitamin D supplementation (12, 13) . Furthermore, the physical tests applied may be subject to a learning effect, i.e., participants may perform better at follow-up measurements as they have learnt how to perform the test at baseline. Furthermore, our data on effect of PTX on measured indices should be interpreted cautiously, as they are purely observational data. Only few results are available from RCTs on the effects of PTX, showing discrepant results. PHPT patients randomized to PTX in a RCT improved in functional capacity and sleepiness following surgical cure (39, 40) . From other RCTs, QoL seem to improve, if the PHPT patients are symptomatic at baseline, whereas QoL did not improve in asymptomatic PHPT patients randomized to PTX (14, 15, 22) .
In conclusion, patients with PHPT and mean 25OHD levels around 50 nmol/l did not benefit from a further increase in plasma 25OHD levels in response to vitamin D supplementation concerning muscle strength, muscle function, postural stability, or QoL. Independent of preoperative vitamin D levels, PTX improved these parameters, suggesting that functional impairments seen in PHPT are caused by PTH or calcium elevations.
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